Rezvan Moniri

Rezvan Moniri

Auto-generated profile, based on publicly available information

Rezvan Moniri

Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
HKHamed Haddad Kashani
Hamed Haddad Kashani
MSMathias Schmelcher
Mathias Schmelcher
HSHamed Sabzalipoor
Hamed Sabzalipoor
EHElahe Seyed Hosseini
Elahe Seyed Hosseini
RMRezvan Moniri
Rezvan Moniri
SUMMARY Staphylococcus aureus is one of the most common pathogens of humans and animals, where it frequently colonizes skin and mucosal membranes. It is of major clinical importance as a nosocomial pathogen and causative agent of a wide array of diseases. Multidrug-resistant strains have become increasingly prevalent and represent a leading cause of morbidity and mortality. For this reason, novel strategies to combat multidrug-resistant pathogens are urgently needed. Bacteriophage-derived enzymes, so-called endolysins, and other peptidoglycan hydrolases with the ability to disrupt cell walls represent possible alternatives to conventional antibiotics. These lytic enzymes confer a high degree of host specificity and could potentially replace or be utilized in combination with antibiotics, with the aim to specifically treat infections caused by Gram-positive drug-resistant bacterial pathogens such as methicillin-resistant S. aureus. LysK is one of the best-characterized endolysins with activity against multiple staphylococcal species. Various approaches to further enhance the antibacterial efficacy and applicability of endolysins have been demonstrated. These approaches include the construction of recombinant endolysin derivatives and the development of novel delivery strategies for various applications, such as the production of endolysins in lactic acid bacteria and their conjugation to nanoparticles. These novel strategies are a major focus of this review.

1 May 2013 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SDS. Doakhan
S. Doakhan
MMM. Montazer
M. Montazer
ARA. Rashidi
A. Rashidi
RMR. Moniri
R. Moniri
MMM.B. Moghadam
M.B. Moghadam

30 June 2017 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
HKHamed Haddad Kashani
Hamed Haddad Kashani
HFHossein Fahimi
Hossein Fahimi
YGYasaman Dasteh Goli
Yasaman Dasteh Goli
RMRezvan Moniri
Rezvan Moniri
Cysteine/histidine-dependent amidohydrolase/peptidase (CHAP) and amidase are known as catalytic domains of the bacteriophage-derived endolysin LysK and were previously reported to show lytic activity against methicillin-resistant Staphylococcus aureus (MRSA). In the current study, the in silico design and analysis of chimeric CHAP-amidase model was applied to enhance the stability and solubility of protein, which was achieved through improving the properties of primary, secondary and tertiary structures. The coding gene sequence of the chimeric CHAP-amidase was synthesized and subcloned into the pET-22(+) expression vector, and the recombinant protein was expressed in E.coli BL21 (DE3) strain. Subsequent affinity-based purification yielded ~12 mg soluble protein per liter of E.coli culture. Statistical analysis indicated that concentrations of ≥ 1 µg/mL of the purified protein have significant antibacterial activity against S.aureus MRSA252 cells. The engineered chimeric CHAP-amidase exhibited 3.2 log reduction of MRSA252 cell counts at the concentration of 10 µg/mL. A synergistic interaction between CHAP-amidase and vancomycin was detected by using checkerboard assay and calculating the fractional inhibitory concentration (FIC) index. This synergistic effect was shown by 8-fold reduction in the minimum inhibitory concentration of vancomycin. The chimeric CHAP-amidase displayed strong antibacterial activity against S.aureus, S.epidermidis and enterococcus. However, it did not indicate any significant antibacterial activity against E.coli and Lactococcus lactis. Taken together, these findings suggest that our chimeric CHAP-amidase might represent potential to be used for the development of efficient antibacterial therapies targeting MRSA and certain Gram-positive bacteria.

1 December 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
NFNeamati Foroogh
Neamati Foroogh
MRMoniri Rezvan
Moniri Rezvan
KAKhorshidi Ahmad
Khorshidi Ahmad
MSMahmood Saffari
Mahmood Saffari

13 September 2018 in BioImpacts
Verified
Journal Article
Open access
PDF file
ASAzam Safary
Azam Safary
RMRezvan Moniri
Rezvan Moniri
MHMaryam Hamzeh-Mivehroud
Maryam Hamzeh-Mivehroud
SDSiavoush Dastmalchi
Siavoush Dastmalchi
Introduction: The bacterial enzyme has gained more attention in therapeutic application because of the higher substrate specificity and longer half-life. L-asparaginase is an important enzyme with known antineoplastic effect against acute lymphoblastic leukemia (ALL). Methods: Novel L-asparaginase genes were identified from a locally isolated halo-thermotolerant Bacillus strain and the recombinant enzymes were overexpressed in modified E. coli strains, OrigamiTM B and BL21. In addition, the biochemical properties of the purified enzymes were characterized, and the enzyme activity was evaluated at different temperatures, pH, and substrate concentrations. Results: The concentration of pure soluble enzyme obtained from Origami strain was ~30 mg/L of bacterial culture, which indicates the significant improvement compared to L-asparaginase produced by E. coli BL21 strain. The catalytic activity assay on the identified L-asparaginases (ansA1 and ansA3 genes) from Bacillus sp. SL-1 demonstrated that only ansA1 gene codes an active and stable homologue (ASPase A1) with high substrate affinity toward L-asparagine. The Kcat and Km values for the purified ASPase A1 enzyme were 23.96s-1 and 10.66 µM, respectively. In addition, the recombinant ASPase A1 enzyme from Bacillus sp. SL-1 possessed higher specificity to L-asparagine than L-glutamine. The ASPase A1 enzyme was highly thermostable and resistant to the wide range of pH 4.5–10. Conclusion: The biochemical properties of the novel ASPase A1 derived from Bacillus sp. SL-l indicated a great potential for the identified enzyme in pharmaceutical and industrial applications.

6 October 2015 in Comparative Clinical Pathology
Verified
Journal Article
Closed access
PDF file
RDRouhullah Dehghani
Rouhullah Dehghani
MSMohammad Reza Sharif
Mohammad Reza Sharif
RMRezvan Moniri
Rezvan Moniri
ASAlireza Sharif
Alireza Sharif
HKHamed Haddad Kashani
Hamed Haddad Kashani